(CE MRA) Contrast enhanced MR angiography is based on the T1 values of blood, the surrounding tissue, and paramagnetic contrast agent.
T1-shortening contrast agents reduces the T1 value of the blood (approximately to 50 msec, shorter than that of the surrounding tissues) and allow the visualization of blood vessels, as the images are no longer dependent primarily on the inflow effect of the blood. Contrast enhanced MRA is performed with a short TR to have low signal (due to the longer T1) from the stationary tissue, short scan time to facilitate breath hold imaging, short TE to minimize T2* effects and a bolus injection of a sufficient dose of a gadolinium chelate.
Images of the region of interest are performed with 3D spoiled gradient echo pulse sequences. The enhancement is maximized by timing the contrast agent injection such that the period of maximum arterial concentration corresponds to the k-space acquisition. Different techniques are used to ensure optimal contrast of the arteries e.g., bolus timing, automatic bolus detection, bolus tracking, care bolus. A high resolution with near isotropic voxels and minimal pulsatility and misregistration artifacts should be striven for. The postprocessing with the maximum intensity projection (MIP) enables different views of the 3D data set.
Unlike conventional MRA techniques based on velocity dependent inflow or phase shift techniques, contrast enhanced MRA exploits the gadolinium induced T1-shortening effects. CE MRA reduces or eliminates most of the artifacts of time of flight angiography or phase contrast angiography. Advantages are the possibility of in plane imaging of the blood vessels, which allows to examine large parts in a short time and high resolution scans in one breath hold. CE MRA has found a wide acceptance in the clinical routine, caused by the advantages:

The spins (protons) go out of phase in the transverse plane when the Rf pulse is switched of. This dephasing is due to static magnetic field inhomogeneities intrinsic (i.e. susceptibility changes at tissue interfaces) and extrinsic (i.e. field inhomogeneities of the main magnetic field) to the examined object.

See also T2*.

Short name: Dy-DOTA-4AmCE, central moiety: Dy2+, contrast effect: T2*enhanced
Dy-DOTA-4AmCE, a macrocyclic complex is characterized by a very slow water exchange, a complex compared with several Dy-DTPA derivatives known for their efficacy as T2 contrast agents at high magnetic fields.

(FLASH) A fast sequence producing signals called gradient echo with low flip angles. FLASH sequences are modifications, which incorporate or remove the effects of transverse coherence respectively.
FLASH uses a semi-random spoiler gradient after each echo to spoil the steady state (to destroy any remaining transverse magnetization) by causing a spatially dependent phase shift. The transverse steady state is spoiled but the longitudinal steady state depends on the T1 values and the flip angle. Extremely short TR times are possible, as a result the sequence provides a mechanism for gaining extremely high T1 contrast by imaging with TR times as brief as 20 to 30 msec while retaining reasonable signal levels. It is important to keep the TE as short as possible to suppress susceptibility artifacts.
The T1 contrast depends on the TR as well as on flip angle, with short TE.
Small flip angles and short TR results in proton density, and long TR in T2* weighting.
With large flip angles and short TR result T1 weighted images.

TR and flip angle adjustment:
TR 3000 ms, Flip Angle 90°
TR 1500 ms, Flip Angle 45°
TR 700 ms, Flip Angle 25°
TR 125 ms, Flip Angle 10°

The apparent ability to trade TR against flip angle for purposes of contrast and the variation in SNR as the scan time (TR) is reduced.

See also Gradient Echo Sequence.

Short name: Gd-DTPA, generic name: Gadopentetate dimeglumine, chemical compound: Gadolinium-diethylenetriaminepentaacetic acid
Gadopentetate dimeglumine was introduced in 1981, as the first paramagnetic MRI contrast agent (ionic). The Gd-induced dipole dipole interactions lead to shortening of T1, which results in contrast enhancement on T1 weighted images. The used metal ion Gd3+ (gadolinium) is toxic, and therefore bound in the renally excreted DTPA chelate, a very stable complex. The Gd-complex also induce susceptibility effects, as a result of the magnetic field gradient between the contrast agent in the blood vessels and the surrounding tissue, that lead to shortening of T2 or T2*.
Following intravenous administration, the compound is distributed rapidly in the extracellular space and is eliminated unchanged by glomerular filtration via the kidneys. Up to 6 hours, post injection an average of 83% of the dose is eliminated renal.

See also Magnevist®, Gadolinium and Contrast Agents.